ReviewFrontiers in immunology2023
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 33 citations in OpenAlex.
- Efficacy and metabolomic analysis of the pneumonia compound formulation against community-acquired pneumonia: an observational controlled before-after clinical trial.BMC infectious diseases · 2025Trial
- Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Vesicles.Biomedicines · 2026Review
- Inflammatory Biomarkers and Clinical Outcomes in Hospitalized Hemodialysis Patients with COVID-19: A Retrospective Observational Study.Diagnostics (Basel, Switzerland) · 2026Article
- Pediatric SARS-CoV-2 outcomes study (PECOS): 12-month longitudinal analysis of post-COVID symptoms in infected versus uninfected participants.Pediatric research · 2026Article
- Hemophagocytic Lymphohistiocytosis Triggered byClinical case reports · 2026Article
- Admission biomarkers and COVID-19 mortality: A retrospective study during Vietnam's pandemic peak.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026Article
- Antiviral Activity of Pyrazolopyrimidine and Triazolopyrimidine Derivatives Against SARS-CoV-2 In Vitro: Identifying PZP25 as a Promising Scaffold.Pathogens (Basel, Switzerland) · 2026Article
- Clinical Manifestations and Mortality Predictors of COVID-19 in Patients Undergoing Chronic Hemodialysis: A Retrospective Cohort Study from Romania.Journal of clinical medicine · 2026Article
- Comparative Assessment of Viral Load Retention in Surgical and Fabric Masks Worn by COVID-19 Patients.Viruses · 2025Article
- Immunohistochemical Analysis of Placental Tissue of Women Infected with SARS-CoV-2 During Pregnancy-A Prospective Clinical Study.International journal of molecular sciences · 2025Article
- A Systematic Review of Genetic Variants in Glutathione S-Transferase Genes and Their Dual Role in SARS-CoV-2 Pathogenesis: From Acute Respiratory Complications to Long COVID.Antioxidants (Basel, Switzerland) · 2025Review
- Protective role of anti-SARS-CoV-2 antibody responses against vital organ related long COVID symptoms.Scientific reports · 2025Article
- Integrated multi-sample transcriptomic analysis of COVID-19 patients against controls using a bioinformatics pipeline.Scientific reports · 2025Article
- Translational Success and Pharmacoeconomic Lessons of Pandemic-Driven Drug Repurposing.Cureus · 2025Review
- Differential DNA methylation 7 months after SARS-CoV-2 infection.Clinical epigenetics · 2025Article
- Physicochemical Properties and Molecular Insights of Favipiravir and Roflumilast Solid Dispersions for COVID-19 Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Article
- SARS-CoV-2 Infection and Its Association with Maternal and Fetal Redox Status and Outcomes: A Prospective Clinical Study.Journal of clinical medicine · 2025Article
- Impact of vaccination against SARS-CoV-2 on mortality risk, ICU admission rate, and hospitalization length in hospitalized COVID-19 patients: a cross-sectional study.BMC infectious diseases · 2025Article
- Role of Artificial Intelligence in Identifying Vital Biomarkers with Greater Precision in Emergency Departments During Emerging Pandemics.International journal of molecular sciences · 2025Article
- Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An unprecedented global pandemic caused by a novel coronavirus named SARS-CoV-2 has created a severe healthcare threat and become one of the biggest challenges to human health and the global economy. As of July 2023, over 767 million confirmed cases of COVID-19 have been diagnosed, including more than 6.95 million deaths. The S protein of this novel coronavirus binds to the ACE2 receptor to enter the host cells with the help of another transmembrane protease TMPRSS2. Infected subjects that can mount an appropriate host immune response can quickly inhibit the spread of infection into the lower respiratory system and the disease may remain asymptomatic or a mild infection. The inability to mount a strong initial response can allow the virus to replicate unchecked and manifest as severe acute pneumonia or prolonged disease that may manifest as systemic disease manifested as viremia, excessive inflammation, multiple organ failure, and secondary bacterial infection among others, leading to delayed recovery, hospitalization, and even life-threatening consequences. The clinical management should be targeted to specific pathogenic mechanisms present at the specific phase of the disease. Here we summarize distinct phases of COVID-19 pathogenesis and appropriate therapeutic paradigms associated with the specific phase of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.